Literature DB >> 16365062

Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells.

Renita Handayani1, Lori Rice, Yuehua Cui, Theresa A Medrano, Von G Samedi, Henry V Baker, Nancy J Szabo, Kathleen T Shiverick.   

Abstract

High consumption of soy isoflavones in Asian diets has been correlated with a lower incidence of clinically important cases of prostate cancer. The chemopreventive properties of these diets may result from an interaction of several types of isoflavones, including genistein and daidzein. The present study investigated the effects of a soy isoflavone concentrate (ISF) on growth and gene expression profiles of PC-3 human prostate cancer cells. Trypan blue exclusion and [3H]-thymidine incorporation assays showed that ISF decreased cell viability and caused a dose-dependent inhibition of DNA synthesis, respectively, with 50% inhibition (IC50) of DNA synthesis at 52 mg/L (P = 0.05). The glucoside conjugates of genistein and daidzein in ISF were converted to bioactive free aglycones in cell culture in association with the inhibition of DNA synthesis. Flow cytometry and Western immunoblot analyses showed that ISF at 200 mg/L caused an accumulation of cells in the G2/M phase of the cell cycle (P < 0.05) and decreased cyclin A by 20% (P < 0.05), respectively. The effect of ISF on the gene expression profile of PC-3 cells was analyzed using Affymetrix oligonucleotide DNA microarrays that interrogate approximately 17,000 human genes. Of the 75 genes altered by ISF, 28 were upregulated and 47 were downregulated (P < 0.05). Further analysis showed that IL-8, matrix metalloproteinase 13, inhibin beta A, follistatin, and fibronectin mRNA levels were significantly reduced, whereas the expression of p21(CIP1), a major cell cycle inhibitory protein, was increased. The effects of ISF on the expression of IL-8 and p21(CIP1) mRNA and protein were validated at high and low ISF concentrations. Our data show that ISF inhibits the growth of PC-3 cells through modulation of cell cycle progression and the expression of genes involved in cell cycle regulation, metastasis, and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16365062     DOI: 10.1093/jn/136.1.75

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  26 in total

1.  Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures.

Authors:  Nagi Kumar; Theresa Crocker; Tiffany Smith; Julio Pow-Sang; Philippe E Spiess; Shanjayla Connors; Ganna Chornukur; Shohreh Iravani Dickinson; Wenlong Bai; Christopher R Williams; Raoul Salup; Wui Fu
Journal:  J Cancer Sci Ther       Date:  2012-01-10

Review 2.  Dietary factors and epigenetic regulation for prostate cancer prevention.

Authors:  Emily Ho; Laura M Beaver; David E Williams; Roderick H Dashwood
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

3.  Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer.

Authors:  Ralph W deVere White; Alexander Tsodikov; Eschelle C Stapp; Stephanie E Soares; Hajime Fujii; Robert M Hackman
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

4.  Soy isoflavones exert differential effects on androgen responsive genes in LNCaP human prostate cancer cells.

Authors:  Lori Rice; Renita Handayani; Yuehua Cui; Theresa Medrano; Von Samedi; Henry Baker; Nancy J Szabo; Charles J Rosser; Steve Goodison; Kathleen T Shiverick
Journal:  J Nutr       Date:  2007-04       Impact factor: 4.798

Review 5.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

6.  Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones.

Authors:  Audrey Arfi; Magali Richard; Christelle Gandolphe; Daniel Scherman
Journal:  J Inherit Metab Dis       Date:  2010-02       Impact factor: 4.982

Review 7.  The relationship between nutrition and prostate cancer: is more always better?

Authors:  Elizabeth M Masko; Emma H Allott; Stephen J Freedland
Journal:  Eur Urol       Date:  2012-11-15       Impact factor: 20.096

8.  Safety of purified isoflavones in men with clinically localized prostate cancer.

Authors:  Nagi B Kumar; Jeffrey P Krischer; Kathy Allen; Diane Riccardi; Karen Besterman-Dahan; Raoul Salup; Lovellen Kang; Ping Xu; Julio Pow-Sang
Journal:  Nutr Cancer       Date:  2007       Impact factor: 2.900

9.  A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer.

Authors:  Nagi B Kumar; Jeffrey P Krischer; Kathy Allen; Diane Riccardi; Karen Besterman-Dahan; Raoul Salup; Lovellen Kang; Ping Xu; Julio Pow-Sang
Journal:  Nutr Cancer       Date:  2007       Impact factor: 2.900

10.  Detection of differentially expressed wound-healing-related glycogenes in galectin-3-deficient mice.

Authors:  Chandrassegar Saravanan; Zhiyi Cao; Steven R Head; Noorjahan Panjwani
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-30       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.